NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Vilde Drageset Haakensen1,2, Anna K. Nowak3,4, Espen Basmo Ellingsen5,6, Saima Jamil Farooqi1,2, Maria Moksnes Bjaanaes1,2, Henrik Horndalsveen1,2, Tine McCulloch7,8, Oscar Grundberg9, Susana M. Cedres10 and Åslaug Helland1,2,11*

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recently shown increased survival compared to standard chemotherapy, but most patients do not respond and improvements are called for. Telomerase is expressed in mesothelioma cells, but only sparsely in normal tissues and is therefore an attractive target for therapeutic vaccination. Vaccination against telomerase is tolerable and has shown to induce immune responses associated with increased survival in other cancer types. There is a well-founded scientific rationale for the combination of a telomerase vaccine and checkpoint inhibition to improve treatment response in MPM patients.

Methods: NIPU is a randomized, multi-centre, open-label, phase II study comparing the efficacy and safety of nivolumab and ipilimumab with or without telomerase vaccine in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy. Participants (n = 118) are randomized 1:1 into two treatment arms. All participants receive treatment with nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) until disease progression, unacceptable toxicity or for a maximum of 2 years. Patients randomised to the experimental arm receive 8 intradermal injections of UV1 vaccine during the first three months of treatment. Tumour tissue, blood, urine, faeces and imaging will be collected for biomarker analyses and exploration of mechanisms for response and resistance to therapy.

Discussion: Checkpoint inhibition is used for treatment of mesothelioma, but many patients still do not respond. Increasing therapy response to immunotherapy is an important goal. Possible approaches include combination with chemotherapy, radiotherapy, targeted therapy and other immunotherapeutic agents. Predictive biomarkers are necessary to ensure optimal treatment for each patient and to prevent unnecessary side effects. This trial seeks...
Background
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour originating from the cells lining the mesothelial surface in the lungs. Median overall survival (OS) is ~ 1 year [1]. Asbestos exposure is linked to development of the disease [2]. Most patients diagnosed with malignant pleural mesothelioma are inoperable and have been treated with cisplatin in combination with pemetrexed which has been the standard of care first-line therapy worldwide since 2003.

Intra-tumour infiltration of CD8+ T cells is associated with improved outcome in MPM [3] and a high expression of PD-L1 is associated with poor prognosis in this group of patients [4]. Monotherapy using pembrolizumab, nivolumab or avelumab has demonstrated a response rate of 9.3–20% [5–7]. The only phase 3 trial combining PD-1 and CTLA4 inhibition (Checkmate 743) showed an increased median survival from 14.1 to 18.1 months, and a duration of response of 11.0 vs 6.7 months in the combination arm vs the chemotherapy arm, respectively [8]. However, almost all the benefit was seen in patients with biphasic or sarcomatoid disease, whereas those with epithelioid disease did not benefit significantly. Grade 3 or 4 toxicity with the combination has been found in 17–34% of patients and has generally been manageable. The most common toxicities have been from the skin, gastrointestinal tract, hormone system and infusion reactions [8]. Based on these results, the FDA approved the combination of ipilimumab and nivolumab in the first line setting in October 2020.

Methods/design
Oslo University Hospital is sponsor of the study. We have established collaborations for patient recruitment with cancer centres in Australia, Denmark, Sweden and Spain. University of Western Australia is sponsor for the study in Australia. Patient recruitment started in June 2020 and is expected to finish by May 2022. Initiation of the trial was postponed due to the COVID-19 pandemic. By March 2021, patients are included in Norway, Australia and Denmark.

Objectives
Primary objective
To evaluate and compare the efficacy of nivolumab and ipilimumab with or without UV1-vaccine in patients with inoperable malignant pleural mesothelioma progressing after first-line platinum-based chemotherapy. The primary end point will be progression free survival (PFS) evaluated by modified response evaluation criteria in solid tumours (mRECIST) [11, 12] as determined by blinded, independent central review (BICR).

Keywords: Malignant pleural mesothelioma, Telomerase vaccine, Immunotherapy, hTERT, Nivolumab, Ipilimumab, Biomarker, Immune response
Secondary objectives

- To compare overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR) and duration of response (DOR) according to Response Evaluation Criteria in Solid Tumours, version 1.1 (Modified RECIST), in patients who receive nivolumab and ipilimumab with patients who receive nivolumab and ipilimumab in combination with UV1.
- To evaluate changes from baseline in patient-reported outcomes (PROs) of lung cancer symptoms, patient functioning, and health-related quality of life (HRQoL) in patients who receive nivolumab and ipilimumab compared to patients who receive nivolumab and ipilimumab in combination with UV1.
- To determine tolerability in patients who receive nivolumab and ipilimumab compared to patients who receive nivolumab and ipilimumab in combination with UV1.

Exploratory/translational objectives

- To characterise the TCR repertoire in patients receiving checkpoint inhibition alone compared with in combination with UV1 vaccination.
- To evaluate tumour mutational burden (TMB) as a predictive biomarker of response to therapy.
- To assess any difference in immune cell infiltration in tumour pre- and post-treatment with checkpoint inhibition alone or with UV1 vaccination.
- To assess vaccine-specific T-cell response in the blood cells of patients treated with UV1 vaccination.
- To assess any correlation between the microbial composition in faeces and treatment response.

- Evaluate dual-time PET as a predictive marker of therapy response and assess the ability of dual-time PET to distinguish between different cell types in the tumour.

Study design

This is a randomized, multi-centre, open-label, proof of concept study comparing the efficacy and safety of nivolumab and ipilimumab with or without UV1 in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy.

The patients (n = 118) will be randomized 1:1 into two treatment arms (see Fig. 1):

A Nivolumab and ipilimumab plus 8 UV1 vaccinations.
B Nivolumab and ipilimumab alone.

Treatment will be continued until disease progression, unacceptable toxicity or for a maximum of 2 years. Because of the potential for pseudo progression/tumour immune infiltration, this study will allow patients to remain on study treatment after apparent radiographic progression, provided the risk/benefit ratio is judged to be favourable.

Biological material will be sampled, and translational explorative analyses will be performed to identify biomarkers and reveal mechanisms of response and resistance.

Dosage

- Nivolumab: 240 mg every 2 weeks for 2 years until progression or unacceptable toxicity.
- Ipilimumab: 1 mg/kg every 6 weeks for 2 years until progression or unacceptable toxicity.

**Fig. 1** Study design of the NIPU trial. Patients with MPM and progression after first line platinum-based chemotherapy are randomised (1:1) to ipilimumab and nivolumab alone or in combination with UV1 vaccine.
- UV1 vaccination (arm A only): 8 intradermal injections with 300 μg UV1 and 75 μg GM-CSF (sargramostim) during the first 13 weeks. The first 3 UV1 vaccinations will begin in week 1, one in week 2, followed by four UV1 vaccinations throughout the following 11 weeks, totalling eight vaccinations. The first three vaccinations of UV1 will be given prior to the first infusion of nivolumab and ipilimumab.

Overview of the study procedures and treatment can be found in Table 1.

**Rationale for the choice of vaccine**
Telomerase activation is a major factor contributing to cancer proliferation, immortality, and invasiveness [13–15], and its activation is documented in MPM [16, 17]. Tumour telomerase expression is correlated with poor outcome for many cancers [18–20], conversely, spontaneously occurring telomerase-directed CD4+ T-cell responses have recently been identified as a positive prognostic factor in NSLCL [21], substantiating its relevance as a target for vaccination in thoracic malignancies. Vaccination with UV1 induces immune responses directed at telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase complex. By targeting this essential cancer protein, there are limited possibilities for resistance mutations to develop, as loss of hTERT would restrict tumour proliferation and metastasis. Furthermore, by mounting a CD4+ Th1 response (i.e. secretion of IFN-γ, TNFα and IL-2), the vaccine aims to induce an inflammatory tumour microenvironment to further stimulate the expansion of secondary effector cells. UV1 is administered with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant. The safety and immunological response of the vaccine given as monotherapy have been investigated in two clinical phase I/II trials [22, 23]. The combination of the UV1 vaccine with ipilimumab in metastatic malignant melanoma patients has been investigated in a phase I/IIa trial (n = 12) (Aamdal E. et al. Manus in prep.) (NCT02275416). Together, these studies have shown that UV1 is generally safe and well tolerated. Common adverse events related to UV1 include pruritus, erythema, fatigue, diarrhoea, pain and rash. Overall, six of the 52 patients vaccinated with UV1 (12%) experienced serious adverse events that were related to UV1 and/or GM-CSF, of these five were of allergic origin. All events resolved without sequelae.

Across the three phase I/II-studies conducted with UV1, vaccine-specific immune responses were observed in 78% (range 67–91%) of patients across the different cancer types (and HLA allele types), supporting the

---

**Table 1** Overview of study treatment and procedures

| Weeks | Study period | Enrolment | Up to 2 years | EOT | Q3M safety FU | Q3M survival FU |
|-------|--------------|-----------|---------------|-----|---------------|-----------------|
| –4–0  | 1            | 2         | 3–5           | 6–7 | 12            | Q6W             |
|       |              | Informed consent | x             |     |               |                 |
|       |              | Randomisation | x             |     |               |                 |
|       |              | Treatment arm A |               |     |               |                 |
|       |              | UV1        | x x x x x x x |     |               |                 |
|       |              | Nivolumab Q2W | x x x x x x x |     |               |                 |
|       |              | Ipilimumb Q6W | x x x x      |     |               |                 |
|       |              | Treatment arm B |               |     |               |                 |
|       |              | Nivolumab Q2W | x x x x x x x |     |               |                 |
|       |              | Ipilimumb Q6W | x x x x      |     |               |                 |
|       |              | Procedures  |               |     |               |                 |
|       |              | CT         | x x x x x x x |     |               |                 |
|       |              | Dual-time PET | x x x x x     |     |               |                 |
|       |              | Biopsy     | x              |     |               |                 |
|       |              | Study blood samples | x x x x x x x x x x |     |               |                 |
|       |              | HR-QoL     | x x x x x     |     |               |                 |
|       |              | Clinical examination Q2W | x x x x x x x x x x x x x |     |               |                 |
|       |              | AE/SAE Q2W  | x x x x x x x x x x x x x |     |               |                 |
|       |              | Disease status/survival | x x x x x x x x x x x x x |     |               |                 |
universality of the vaccine. Survival time for patients who responded immunologically was longer than for patients who did not respond immunologically to the vaccine, and survival time correlated with the breadth of the vaccine-specific immune response.

In summary, UV1 is safe alone and in combination with checkpoint inhibitors and trials in other cancers show that UV1 induces vaccine-specific immune response associated with survival.

Rationale for the choice of immunotherapy

The rationale for combining UV1 vaccination with immune checkpoint inhibitors is for the vaccine to prime a meaningful T cell response that can be enhanced by the checkpoint inhibitors to facilitate the activity of the tumour-specific T cells in the tumour microenvironment. Several pre-clinical studies have shown improved anti-tumour responses upon combination of vaccine and checkpoint inhibitors [24]. Data from clinical studies combining anti-immune checkpoint blockade and vaccines are still limited, but some early trials show encouraging results and were recently reviewed [25]. PD-1 and CTLA-4 checkpoints differentially affect CD8+ and CD4+ T-cell phenotypes [26] and recent data indicate that immune responses induced by anti-CTLA-4 and anti-PD-1 checkpoint-blockade are driven by different cellular mechanisms [27]. This indicates that vaccination with long peptides containing both CD4 and CD8 T-cell epitopes combined with both ipilimumab and nivolumab could be expected to have a maximal synergistic effect.

UV1-specific immune responses were induced in 11 out of 12 melanoma-patients treated with UV1 vaccine in combination with ipilimumab. The immune response appeared more frequently and rapidly than in patients treated with UV1 alone [22], [23] (Aamlid et al. manuscript submitted), suggesting a synergistic effect of blocking of CTLA-4 and vaccination with UV1. Of 12 patients, one patient developed a complete response, three patients obtained a partial response, and two achieved stable disease as best overall response. The safety, clinical and immunological responses of the UV1 vaccine when used in combination with the PD-1 immune checkpoint inhibitor pembrolizumab is currently under investigation in a phase I/II clinical trial in patients (N = 30) with metastatic malignant melanoma (NCT03538314).

In summary, ipilimumab and nivolumab has shown clinical benefit in patients with MPM and trials in other tumour groups have found immunological synergy between ipilimumab and UV1.

Patient selection

Selected inclusion and exclusion criteria are shown in Table 2.

Safety measures

Handling of toxicities

Administration of study treatment will be performed in a setting with emergency medical facilities and staff who are trained to monitor for and respond to medical emergencies. All adverse events and serious adverse events will be recorded during the trial and for up to 30 days after the last dose of study drug or until the initiation of another anti-cancer therapy, whichever occurs first. After this period, investigators should report serious adverse events and adverse events of special interest that are believed to be related to prior treatment with study drug. Events will be graded according to NCI CTCAE v5.0.

Table 2 Selected inclusion and exclusion criteria

| Selected inclusion criteria                                                                 | Selected exclusion criteria                                                                 |
|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| 1. Histologically and/or cytologically confirmed MPM                                        | 1. Disease suitable for curative surgery                                                  |
| 2. Unresectable disease, not candidate for curative surgery                                  | 2. Previous treatment with a PD1 or PD-L1 inhibitor                                        |
| 3. Measurable disease, defined as at least one lesion (CT or MRI) that is suitable for repeated assessment |
| 4. Available unstained archived tumour tissue sample                                         | 4. Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ |
| 5. Previously treated with at least one line of platinum doublet                             | 5. Symptomatic or uncontrolled brain metastases requiring concurrent treatment           |
| 6. ECOG performance status of 0–1                                                             | 6. Known history of leptomeningeal carcinomatosis                                         |
| 7. Willing to provide archived tumour tissue and blood samples for research                  | 7. Active or prior documented autoimmune or inflammatory disorders                       |
| 8. Adequate organ function                                                                    | 8. History of primary immunodeficiency                                                   |
| 9. Age ≥ 18 years                                                                             | 9. History of allogeneic organ transplant                                                 |
| 10. Uncontrolled intercurrent illness                                                          | 10. Active infection                                                                    |
| 11. Active infection                                                                          | 11. Uncontrolled intercurrent illness                                                        |
Dose reduction considerations (selected points)

- Dose reduction of nivolumab or ipilimumab is not permitted, apart from changing the dosing intervals for ipilimumab to every 12th week.
- For any concomitant conditions already apparent at baseline, the dose modifications will apply according to the corresponding shift in toxicity grade, if the investigator feels it is appropriate. For example, if a patient has grade 1 asthenia at baseline that increases to grade 2 during treatment, this will be considered a shift of one grade and treated as grade 1 toxicity for dose-modification purposes.
- When several toxicities with different grades of severity occur at the same time, the dose modifications should be according to the highest grade observed.
- If, in the opinion of the investigator, a toxicity is considered to be due to some component of the treatment leading to a dose delay, the other component(s) may be administered if there is no contraindication.
- If a patient experiences a grade 3 or 4 adverse event considered probably related to ipilimumab, the ipilimumab dosing interval should be extended to every 12 weeks. The ipilimumab dose should be kept at 1mg/kg.
- Patients may temporarily suspend study treatment with nivolumab/ipilimumab if they experience an adverse event that requires a dose to be held.
  - If nivolumab is held because of adverse events for > 42 days (6 weeks), the patient will be discontinued from nivolumab treatment.
  - If ipilimumab is held because of adverse events for > 126 days (18 weeks), the patient will be discontinued from nivolumab treatment.
  - If the patient is likely to benefit from resuming nivolumab/ipilimumab after a longer hold than allowed (6 or 18 weeks), the study drug may be restarted with the approval of the Sponsor. If a patient must be tapered off steroids used to treat adverse events, nivolumab may be held for > 42 days until steroids are discontinued or reduced to prednisone dose equivalent \(\leq 10\) mg/day.
- The treating physician may use discretion in modifying or accelerating the dose modification guidelines described depending on the severity of toxicity and an assessment of the risk versus benefit for the patient, with the goal of maximizing patient compliance and access to supportive care.
- Dose modification of GM-CSF (sargramostim) or UV1 is not allowed in this study. If ipilimumab and nivolumab are withheld during the study treatment period, UV1 vaccination must also be withheld. UV1 vaccinations will only be reintroduced if both ipilimumab and nivolumab are reintroduced.
- UV1 vaccination and/or ipilimumab and nivolumab not administered will not be replaced during the study treatment period.

Independent data monitoring

An independent data monitoring committee (IDMC) has pre-planned assessment of the safety of the trial 4 and 13 weeks after the first 6 and 14 patients have started treatment. All the IDMC assessments has been successfully completed.

Sample collection/biobanking

An extensive research program will be conducted. The patient informed consent form will allow for performing biomarker analyses, immunological studies, gene profiling and studies of tumour evolution/heterogeneity during treatment, as well as comparison with data/material from other studies.

1. Tumour biopsies collected pre, during and post therapy (time of progression). If sufficient tissue is available, three biopsies will be obtained at each timepoint, and prioritized in the following order:
   - (a) FFPE tissue.
   - (b) Snap-frozen tumour biopsies.
   - (c) Fresh tumour cells/tumour infiltrating lymphocytes frozen as cell suspension (selected sites).

2. A separate biopsy (snap-frozen) will be taken at week 6 from those patients who consent to the procedures.

3. Blood samples collected pre-, during and post-therapy:
   - (a) Peripheral blood mononuclear cells, processed with gradient centrifugation and frozen on liquid nitrogen (selected sites).
   - (b) Plasma/serum, separated and frozen.
   - (c) Circulating tumour cells (only if sufficient resources available).

4. Urine samples collected pre-, during and post-therapy.

5. Faecal samples collected at baseline, tumour evaluation timepoints and progression.

6. Dual-time PET analyses at baseline, 6 weeks, 1 year and at progression (selected sites).
Statistical analyses
Under the null hypothesis, the PFS hazard ratio (HR), for ipilimumab and nivolumab in combination with UV1 (ipi/nivo/UV1) vs ipilimumab and nivolumab (ipi/nivo) is assumed to be 1.00. Under the alternative hypothesis, the HR is assumed to be 0.60. To test the null hypothesis with 80% power and a 1-sided alpha level of 0.10, a total of 69 PFS events are required. Based on the INITIATE trial [28], with 12 months median follow-up it is expected that 69% of patients treated with ipi/nivo will have progressed and, with a HR of 0.60, it is further expected that 51% of patients treated with ipi/nivo/UV1 will have progressed. With an expected accrual rate of 5 patients per month, a total N=118 patients randomized into the trial over a 24-month period and followed for a minimum of 2–3 months after the last patient is randomized will yield the 69 PFS events required.

Discussion
The NIPU study is designed as a randomized phase 2 trial. Randomization will provide useful data on both toxicity and efficacy. Since the combination of UV1 with ipilimumab and nivolumab has not previously been studied in patients with MPM, a phase 2 study giving indications of both toxicity and efficacy is warranted before starting a phase 3 trial for both ethical and economic reasons. The trial is open-labelled as placebo vaccination with observation time was impractical and time-consuming for both patients and nurses and blinding was not considered necessary for a phase 2 trial with a blinded independent centrally reviewed primary endpoint.

As treatment guidelines change, the patient population eligible for clinical trials change. One challenge with the NIPU trial is that patients treated with checkpoint inhibition in first line are not eligible for the trial and once the ipilimumab/nivolumab treatment regime is implemented, the patient population eligible for the study will rapidly reduce. Until that time, however, the patients have few treatment options in the second line and the clinical data gained from this trial may be relevant for the first line setting in the future. Inclusion has started and shows that patients are eager to participate in the trial.

The translational analyses constitute an important part of the trial. As immunotherapy is being established as part of the treatment available to patients with MPM, it is important to gain knowledge about biological mechanisms contributing to treatment response or resistance.

Tumour biopsies will be collected at baseline and at 6 weeks after start of treatment to evaluate the tumour microenvironment and its association with therapy effect. Characterization of immune cell subsets will be done in the tumour and in the circulation, including T-cells, B cells, NK cells, myeloid-derived suppressor cells, or subpopulations Immune cells in the tumour will be characterized. Specific immune response against the UV1 vaccine will be analysed as will the changes in clonality of the T cell receptor repertoire in response to therapy.

Previous studies have shown that the temporal dynamics of uptake of 18F-Fluorodeoxyglucose (FDG) varies between benign and malignant lesions [29, 30]. The uptake kinetics of FDG (reflected by glucose consumption rates) may vary between different cell types, and we hypothesize that we can differentiate between cancer and immune cells by so-called dual-time PET [29]. We test this by comparing the cellular composition (tumour cells and various immune cells) at baseline and at 6 weeks after treatment with dual-time PET (scans obtained 60 and 120 min after injection of FDG).

The composition of the gut microbiome has been found associated with response to immunotherapy and the use of antibiotics has been associated with reduced effect of check point inhibition as a result of unfavourable alterations to the gut microbiome [31, 32]. We collect faeces at baseline, 6 weeks, at regular intervals and at progression for DNA extraction and deep sequencing. Microbiota profiles will be linked to immune responses in circulation and in the tumour to identify microbes associated with immune response to treatment. Information about concomitant medication will be available.

Exploration of biological mechanisms of action and biomarker analyses will be performed on tumour tissue, but we will also search for reliable biomarkers using less invasive methods such as blood, imaging, urine and faeces. Based on results from the CheckMate 743 trial indicating more pronounced benefit for sarcomatoid/non-epithelioid tumours [8], the clinical effect and the biological basis for the effect in the epithelioid and non-epithelioid tumours will be explored. The knowledge gained from these translational studies will be of value in understanding the mechanisms for therapy effect and resistance also in the first line setting.

Abbreviations
BICR: Blinded, independent central review; CTCAE: Common terminology criteria for adverse events; CTLA4: Cytotoxic T-lymphocyte-associated protein 4; DCR: Disease control rate; DOR: Duration of response; FDA: Food and drug administration; FFPE: Formalin-fixed paraffin-embedded; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HR: Hazard ratio; HRQoL: Health-related quality of life; MPM: Malignant pleural mesothelioma; mRECIST: Modified response evaluation criteria in solid tumours; NCI: National cancer institute; NIPU: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma; ORR: Objective response rate; OS: Overall survival; PET: Positron emission tomography; PD-L1: Programmed death-ligand 1; PFS: Progression emission tomography; PROs:
Page 8 of 9

Patient-reported outcomes; TMB: Tumour mutational burden; TTR: Time to response.

Acknowledgements
The authors thank study nurses, project managers, engineers and lab personnel in all hospitals including patients for their valuable contribution to the trial. We also highly value the collaboration with BMS and Ultrimovacs and thank the South-Eastern Norway regional health authority for their funding. AKN acknowledges funding from the National Health and Medical Research Council (Australia) for the National Centre for Asbestos Related Diseases Centre of Research Excellence (APP1197652).

Authors’ contributions
VDH: clinical investigator, attract funding, contribution to protocol revision, writing manuscript. AKN: clinical investigator. EBE: contribution to preparation of the trial. SJF: clinical investigator, PhD student. AKN, MMH, HH, OG and SC: Clinical investigators. AH: principal investigator, preparation of trial, attract funding and writing of protocol. All authors read and approved the final manuscript.

Funding
Ultrimovacs provides UV1 vaccine and sargramostin for patients treated in arm A and some funding for the clinical trial. BMS provides ipilimumab and nivolumab for all patients. The South-Eastern Norway regional health authority has provided support for the clinical trial, PhD students and research analyses of the manuscript. SJF: clinical investigator, PhD student. AKN, MMH, HH, OG and SC: Attraction funding, contribution to protocol revision, and writing manuscript. VDH: clinical investigator, attract funding, contribution to protocol revision, writing manuscript.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
The trial is approved by the regional ethics committee (20/47804). All patients sign informed consent after receiving oral and written information and can withdraw from the study at any time point. The study is performed in compliance with the World Medical Association Declaration of Helsinki and ICH E6 for Good Clinical Practice and is approved by the regional ethics committee.

Consent for publication
All authors have consented to the publication. Approval has also been obtained from BMS and Ultrimovacs.

Competing interests
All authors declare no competing interests.

Author details
1 Department of Oncology, Oslo University Hospital, Oslo, Norway. 2 Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 3 National Centre for Asbestos Related Diseases, Institute for Respiratory Health, University of Western Australia, Perth, Australia. 4 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia. 5 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 6 Ultrimovacs, Oslo, Norway. 7 Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 8 Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. 9 Thoracic Oncology Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. 10 Oncology Department, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain. 11 Faculty of Medicine, University of Oslo, Oslo, Norway.

Received: 10 April 2021 Accepted: 22 May 2021 Published online: 31 May 2021

References
1. Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg. 2018;105:432–7. https://doi.org/10.1016/j.athoracsur.2017.09.036.
2. Katzman D, Sterman DH. Updates in the diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Pulm Med. 2018;24:319–26. https://doi.org/10.1097/MCP.0000000000000489.
3. Yamada N, Ozumi S, Kikuchi E, Shinagawa N, Konishi-Skakibara J, Ishimine A, et al. CDB 4–tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1545–9. https://doi.org/10.1007/s00262-010-0881-6.
4. Cedrés S, Ponce-áix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Medival A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;1:1–12. https://doi.org/10.1371/journal.pone.0121071.
5. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piberdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet. 2017;186:623–30.
6. Quispel-janssen J, Van Der NV, De VJF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569–76. https://doi.org/10.1016/j.jtho.2018.05.038.
7. Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, et al. Efficacy and safety ofavelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2020;6:351–7. https://doi.org/10.1001/jamaoncol.2018.5428.
8. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. Articles first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;6736:1–12. https://doi.org/10.1016/S0140-6736(20)32714-8.
9. Raniki T, Joensuu T, Eike J, Karbach J, Wahle C, Kairemo K, et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CDB C T-cell response, prominent in filtration of CDB C lymphocytes and Th1 type polarization. Oncimunology. 2014;3:e958937.
10. Zanetti M. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol. 2017;14:115–28.
11. Armato SG, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol. 2018;13:1012–21. https://doi.org/10.1016/j.jtho.2018.04.034.
12. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–64. https://doi.org/10.1093/annonc/mdh059.
13. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, et al. Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell–like traits in cancer cells. Oncogene. 2013;32:4203–13. https://doi.org/10.1038/onc.2012.441.
14. Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 2018;592:2023–31. https://doi.org/10.1002/1873-3468.13084.
15. Stewart SA, Hahn WC, Connor BF, Banner EN, Lundberg AS, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. PNAS. 2002;99:1–6.
16. Dhane K, Hubner R, Kumar-singh S, Weyn B, Van ME. Telomerase activity in human pleural mesothelioma. Thorax. 1998;53:915–8.
17. Tallet A, Nault J, Renier A, Hysi I, Gallateau-Sallé F, Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene. 2014;33:3748–52. https://doi.org/10.1038/onc.2013.351.
18. Taga S, Osaki T, Ogami A, Imoto H, Yasumoto K. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg. 1999;230:715–20.
19. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer. 2013;108:278–84. https://doi.org/10.1038/bjc.2012.602.

20. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874–81.

21. Laheurte C, Dosset M, Vernerey D, Boullerot L, Gauqler B, Gravelin E, et al. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+ /TIM-3+ T cells in lung cancer. Br J Cancer. 2019;121:405–16. https://doi.org/10.1038/s41416-019-0531-5.

22. Lilleby W, Gaudernack G, Brunsvig PF, Matkovics L, Schulz M, Mills K, et al. Phase I/II clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother. 2017;66:891–901. https://doi.org/10.1007/s00262-017-1994-y.

23. Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-reisse CH, Rasch W, Kyte JA, et al. Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer. Front Immunol. 2020;11:1–12. https://doi.org/10.3389/fimmu.2020.572172.

24. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J Immunother. 2015;38:1–11. https://doi.org/10.1097/CJI.0000000000000062. PD-1/PD-L1.

25. Curran MA, Glisson BS. New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Ann Rev Med. 2019;70:109–24.

26. Wei SC, Sharma R, Anang NAS, Levine JH, Mancuso JJ, Setty M, et al. Negative costimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity. 2019;50:1084–98. https://doi.org/10.1016/j.immuni.2019.03.004.Negative.

27. Wei SC, Levine JH, Wargo JA, Pe D, Allison JP, Wei SC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120-1125.e17. https://doi.org/10.1016/j.cell.2017.07.024.

28. Disselhorst MJ, Quispel-janssen J, Lalazafi F, Monkhorst K, De VJF, Van Der NM, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7:260–70.

29. Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med. 2012;42:267–80. https://doi.org/10.1053/j.semnuclmed.2012.02.003.

30. Sa R, Zhao HG, Dai YY, Guan F. The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions. Med (United States). 2018;97:e12521. https://doi.org/10.1097/MD.0000000000001251.

31. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–44. https://doi.org/10.1093/annonc/mdy103.

32. Zitvogel L, Raoul D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359:1366–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.